Sitemap > Breaking Research > Cancer Immunotherapy
Displaying 901 - 950 of 1868 results
- MDA-7/IL-24, a novel tumor suppressor/cytokine is ubiquitinated and regulated by the ubiquitin-proteasome system, and inhibition of MDA-7/IL-24 degradation enhances the antitumor activity.
- CpG-ODN but not other TLR-ligands restore the antitumor responses in old mice: the implications for vaccinations in the aged.
- Design and conduct of phase II studies of targeted anticancer therapy: Recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT).
- Enhancement of oral drug absorption-Effect of lipid conjugation on the enzymatic stability and intestinal permeability of l-Glu-l-Trp-NH(2).
- Optimizing clinical care of patients with metastatic breast cancer: a new oral vinorelbine plus trastuzumab combination.
- The new tumor suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of pro-angiogenic molecules by myeloma cells and suppresses hypoxia inducible factor (HIF)-1{alpha} activity being involved in myeloma-induced angiogenesis.
- Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated-macrophage-like cells.
- Modulation of Cell-Mediated Immune Response in B16F-10 Melanoma-Induced Metastatic Tumor-Bearing C57BL/6 Mice by Sulforaphane.
- PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final Result of a Phase 2 Study.
- Antitumor Necrosis Factor (TNF-a) Antibodies in the Treatment of Renal Cell Cancer.
- TLR agonists induce the differentiation of human bone marrow CD34(+) progenitors into CD11c(+) CD80/86(+) DC capable of inducing a Th1-type response.
- An oncolytic mutant of herpes simplex virus type-1 in which replication is governed by a promoter/enhancer of human papillomavirus type-16.
- Antitumour activity of cationic-liposome-conjugated adenovirus containing the CCL19 [chemokine (C-C motif) ligand 19] gene.
- Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines.
- Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer providing a potential target for therapy.
- Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system.
- Fc Optimization of Therapeutic Antibodies Enhances Their Ability to Kill Tumor Cells In vitro and Controls Tumor Expansion In vivo via Low-Affinity Activating Fc{gamma} Receptors.
- Mechanisms Involved in Synergistic Anticancer Immunity of Anti-4-1BB and Anti-CD4 Therapy.
- Low-dose Paclitaxel prior to intratumoral dendritic cell vaccine modulates intratumoral cytokine network and lung cancer growth.
- Fas ligand delivery by a prostate-restricted replicative adenovirus enhances safety and antitumor efficacy.
- Bortezomib Sensitizes Non Hodgkin's Lymphoma Cells to Apoptosis Induced by Antibodies to Tumor Necrosis Factor Related Apoptosis-Inducing Ligand (TRAIL) Receptors TRAIL-R1 and TRAIL-R2.
- Combination Treatment with TRA-8 Anti Death Receptor 5 Antibody and CPT-11 Induces Tumor Regression in an Orthotopic Model of Pancreatic Cancer.
- A Divalent Hapten-Peptide Induces Apoptosis in Human Non Hodgkin Lymphoma Cell Lines Targeted by Anti-CD20 x Anti-Hapten Bispecific Antibodies.
- Radioimmunotherapy with {alpha}-Particle Emitting 213Bi-C-Functionalized trans-Cyclohexyl-Diethylenetriaminepentaacetic Acid-Humanized 3S193 Is Enhanced by Combination with Paclitaxel Chemotherapy.
- Binding Activities and Antitumor Properties of a New Mouse/Human Chimeric Antibody Specific for GD2 Ganglioside Antigen.
- Epigenetic control of the immune escape mechanisms in malignant carcinomas.
- Randomized Phase II Trial of Cetuximab, Bevacizumab, and Irinotecan Compared With Cetuximab and Bevacizumab Alone in Irinotecan-Refractory Colorectal Cancer: The BOND-2 Study.
- Randomized Phase II Study of Erlotinib Combined With Bevacizumab Compared With Bevacizumab Alone in Metastatic Renal Cell Cancer.
- Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma.
- Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer.
- Lymphocytes genetically modified to express tumor antigens target DCs in vivo and induce antitumor immunity.
- Targeting adenovirus to CD80 and CD86 receptors increases gene transfer efficiency to malignant glioma cells.
- Recombinant interleukin-12 and interleukin-18 antitumor therapy in a guinea-pig hepatoma cell implant model.
- Effective second-line treatment with cetuximab and bevacizumab in a patient with hepatic metastases of colorectal cancer and hyperbilirubinemia.
- Phase II trial of pegylated interferon and thalidomide in malignant metastatic melanoma.
- In Vivo Targeting of DC-SIGN-positive Antigen-presenting Cells in a Nonhuman Primate Model.
- In Vivo Targeting of Antigens to Human Dendritic Cells Through DC-SIGN Elicits Stimulatory Immune Responses and Inhibits Tumor Growth in Grafted Mouse Models.
- Cross-linking of CD54 on Burkitt Lymphoma Cell Line Raji and Ramos Induces FasL Expression by Reactive Oxygen Species and Apoptosis of Adjacent Cells in Fas/FasL Interaction.
- CMRF-56 Immunoselected Blood Dendritic Cell Preparations Activated With GM-CSF Induce Potent Antimyeloma Cytotoxic T-cell Responses.
- Phase I/II Study of Vaccination With Electrofused Allogeneic Dendritic Cells/Autologous Tumor-derived Cells in Patients With Stage IV Renal Cell Carcinoma.
- Vaccination of Metastatic Colorectal Cancer Patients With Matured Dendritic Cells Loaded With Multiple Major Histocompatibility Complex Class I Peptides.
- Role of Chemotherapy With Gemcitabine Plus 5-fluorouracil and Chemoimmunotherapy in Metastatic Renal Cell Cancer (mRCC).
- Human papillomavirus (HPV) genotype distribution in invasive cervical cancers in France: EDITH study.
- The potential of peroxisome proliferator-activated receptor gamma (PPARgamma) ligands in the treatment of hematological malignancies.
- A chitosan hydrogel-based cancer drug delivery system exhibits synergistic antitumor effects by combining with a vaccinia viral vaccine.
- IL-21 synergizes with IL-7 to augment expansion and anti-tumor function of cytotoxic T cells.
- Cancer Mucosa Antigens as a Novel Immunotherapeutic Class of Tumor-associated Antigen.
- Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo.
- HIV vector-mediated targeted suicide gene therapy for adult T-cell leukemia.
- Antitumor effects in vitro and in vivo and mechanisms of protection against melanoma B16F10-Nex2 cells by fastuosain, a cysteine proteinase from Bromelia fastuosa.